1
|
Wilson DS, Hirosue S, Raczy MM, Bonilla-Ramirez L, Jeanbart L, Wang R, Kwissa M, Franetich JF, Broggi MAS, Diaceri G, Quaglia-Thermes X, Mazier D, Swartz MA, Hubbell JA. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat Mater 2019; 18:175-185. [PMID: 30643235 DOI: 10.1038/s41563-018-0256-5] [Citation(s) in RCA: 143] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 11/20/2018] [Indexed: 05/17/2023]
Abstract
Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antigens, elicits robust humoral and cellular immunity. p(Man-TLR7) is a random copolymer composed of monomers that either target dendritic cells (DCs) via mannose-binding receptors or activate DCs via Toll-like receptor 7 (TLR7). Protein antigens are conjugated to p(Man-TLR7) via a self-immolative linkage that releases chemically unmodified antigen after endocytosis, thus amplifying antigen presentation to T cells. Studies with ovalbumin (OVA)-p(Man-TLR7) conjugates demonstrate that OVA-p(Man-TLR7) generates greater humoral and cellular immunity than OVA conjugated to polymers lacking either mannose targeting or TLR7 ligand. We show significant enhancement of Plasmodium falciparum-derived circumsporozoite protein (CSP)-specific T-cell responses, expansion in the breadth of the αCSP IgG response and increased inhibition of sporozoite invasion into hepatocytes with CSP-p(Man-TLR7) when compared with CSP formulated with MPLA/QS-21-loaded liposomes-the adjuvant used in the most clinically advanced malaria vaccine. We conclude that our antigen-p(Man-TLR7) platform offers a strategy to enhance the immunogenicity of protein subunit vaccines.
Collapse
Affiliation(s)
- D Scott Wilson
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Sachiko Hirosue
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Michal M Raczy
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Leonardo Bonilla-Ramirez
- Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Paris, France
| | - Laura Jeanbart
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Ruyi Wang
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Marcin Kwissa
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Jean-Francois Franetich
- Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Paris, France
| | - Maria A S Broggi
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Giacomo Diaceri
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Xavier Quaglia-Thermes
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Dominique Mazier
- Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Paris, France
| | - Melody A Swartz
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA
| | - Jeffrey A Hubbell
- Institute for Bioengineering, School of Life Science and School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Institute for Molecular Engineering, University of Chicago, Chicago, IL, USA.
| |
Collapse
|
2
|
Bonilla-Ramirez L, Rios A, Quiliano M, Ramirez-Calderon G, Beltrán-Hortelano I, Franetich JF, Corcuera L, Bordessoulles M, Vettorazzi A, López de Cerain A, Aldana I, Mazier D, Pabón A, Galiano S. Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies. Eur J Med Chem 2018; 158:68-81. [PMID: 30199706 DOI: 10.1016/j.ejmech.2018.08.063] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2018] [Revised: 08/21/2018] [Accepted: 08/23/2018] [Indexed: 01/11/2023]
Abstract
Emergence of drug resistance and targeting all stages of the parasite life cycle are currently the major challenges in antimalarial chemotherapy. Molecular hybridization combining two scaffolds in a single molecule is an innovative strategy for achieving these goals. In this work, a series of novel quinoxaline 1,4-di-N-oxide hybrids containing either chloroquine or primaquine pharmacophores was designed, synthesized and tested against both chloroquine sensitive and multidrug resistant strains of Plasmodium falciparum. Only chloroquine-based compounds exhibited potent blood stage activity with compounds 4b and 4e being the most active and selective hybrids at this parasite stage. Based on their intraerythrocytic activity and selectivity or their chemical nature, seven hybrids were then evaluated against the liver stage of Plasmodium yoelii, Plasmodium berghei and Plasmodium falciparum infections. Compound 4b was the only chloroquine-quinoxaline 1,4-di-N-oxide hybrid with a moderate liver activity, whereas compound 6a and 6b were identified as the most active primaquine-based hybrids against exoerythrocytic stages, displaying enhanced liver activity against P. yoelii and P. berghei, respectively, and better SI values than primaquine. Although both primaquine-quinoxaline 1,4-di-N-oxide hybrids slightly reduced the infection of mosquitoes, they inhibited sporogony of P. berghei and compound 6a showed 92% blocking of transmission. In vivo liver efficacy assays revealed that compound 6a showed causal prophylactic activity affording parasitaemia reduction of up to 95% on day 4. Absence of genotoxicity and in vivo acute toxicity were also determined. These results suggest the approach of primaquine-quinoxaline 1,4-di-N-oxide hybrids as new potential dual-acting antimalarials for further investigation.
Collapse
Affiliation(s)
- Leonardo Bonilla-Ramirez
- Grupo Malaria, Facultad de Medicina, Universidad de Antioquía (UdeA), Sede de Investigación Universitaria (SIU), Medellín, Colombia
| | - Alexandra Rios
- Grupo Malaria, Facultad de Medicina, Universidad de Antioquía (UdeA), Sede de Investigación Universitaria (SIU), Medellín, Colombia
| | - Miguel Quiliano
- Universidad de Navarra, Institute of Tropical Health (ISTUN), Campus Universitario, 31008, Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Organic and Pharmaceutical Chemistry, Campus Universitario, 31008, Pamplona, Spain
| | - Gustavo Ramirez-Calderon
- Grupo Malaria, Facultad de Medicina, Universidad de Antioquía (UdeA), Sede de Investigación Universitaria (SIU), Medellín, Colombia
| | - Iván Beltrán-Hortelano
- Universidad de Navarra, Institute of Tropical Health (ISTUN), Campus Universitario, 31008, Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Organic and Pharmaceutical Chemistry, Campus Universitario, 31008, Pamplona, Spain
| | - Jean François Franetich
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL, 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Luis Corcuera
- Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Organic and Pharmaceutical Chemistry, Campus Universitario, 31008, Pamplona, Spain
| | - Mallaury Bordessoulles
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL, 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Ariane Vettorazzi
- Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Pharmacology and Toxicology, 31008, Pamplona, Spain
| | - Adela López de Cerain
- Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Pharmacology and Toxicology, 31008, Pamplona, Spain
| | - Ignacio Aldana
- Universidad de Navarra, Institute of Tropical Health (ISTUN), Campus Universitario, 31008, Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Organic and Pharmaceutical Chemistry, Campus Universitario, 31008, Pamplona, Spain
| | - Dominique Mazier
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL, 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Adriana Pabón
- Grupo Malaria, Facultad de Medicina, Universidad de Antioquía (UdeA), Sede de Investigación Universitaria (SIU), Medellín, Colombia
| | - Silvia Galiano
- Universidad de Navarra, Institute of Tropical Health (ISTUN), Campus Universitario, 31008, Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Organic and Pharmaceutical Chemistry, Campus Universitario, 31008, Pamplona, Spain.
| |
Collapse
|
3
|
Quiliano M, Pabón A, Moles E, Bonilla-Ramirez L, Fabing I, Fong KY, Nieto-Aco DA, Wright DW, Pizarro JC, Vettorazzi A, López de Cerain A, Deharo E, Fernández-Busquets X, Garavito G, Aldana I, Galiano S. Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery. Eur J Med Chem 2018; 152:489-514. [PMID: 29754074 DOI: 10.1016/j.ejmech.2018.04.038] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Revised: 04/16/2018] [Accepted: 04/18/2018] [Indexed: 01/09/2023]
Abstract
Design, synthesis, structure-activity relationship, cytotoxicity studies, in silico drug-likeness, genotoxicity screening, and in vivo studies of new 1-aryl-3-substituted propanol derivatives led to the identification of nine compounds with promising in vitro (55, 56, 61, 64, 66, and 70-73) and in vivo (66 and 72) antimalarial profiles against Plasmodium falciparum and Plasmodium berghei. Compounds 55, 56, 61, 64, 66 and 70-73 exhibited potent antiplasmodial activity against chloroquine-resistant strain FCR-3 (IC50s < 0.28 μM), and compounds 55, 56, 64, 70, 71, and 72 showed potent biological activity in chloroquine-sensitive and multidrug-resistant strains (IC50s < 0.7 μM for 3D7, D6, FCR-3 and C235). All of these compounds share appropriate drug-likeness profiles and adequate selectivity indexes (77 < SI < 184) as well as lack genotoxicity. In vivo efficacy tests in a mouse model showed compounds 66 and 72 to be promising candidates as they exhibited significant parasitemia reductions of 96.4% and 80.4%, respectively. Additional studies such as liver stage and sporogony inhibition, target exploration of heat shock protein 90 of P. falciparum, targeted delivery by immunoliposomes, and enantiomer characterization were performed and strongly reinforce the hypothesis of 1-aryl-3-substituted propanol derivatives as promising antimalarial compounds.
Collapse
Affiliation(s)
- Miguel Quiliano
- Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Campus Universitario, 31008 Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Campus Universitario, 31008 Pamplona, Spain
| | - Adriana Pabón
- Grupo Malaria, Universidad de Antioquía, Medellín, Colombia
| | - Ernest Moles
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, 08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal), Barcelona Center for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain; Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain
| | | | - Isabelle Fabing
- Laboratoire de Synthese et Physicochimie de Molécules d'Intéret Biologique SPCMIB-UMR5068, CNRS - Université Paul Sabatier, 118, route de Narbonne, 31062, Toulouse Cedex 09, France
| | - Kim Y Fong
- Department of Chemistry, Vanderbilt University, Station B 351822, Nashville, TN 37235, USA
| | - Diego A Nieto-Aco
- Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Campus Universitario, 31008 Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Campus Universitario, 31008 Pamplona, Spain
| | - David W Wright
- Department of Chemistry, Vanderbilt University, Station B 351822, Nashville, TN 37235, USA
| | - Juan C Pizarro
- Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University USA; Vector-Borne Infectious Diseases Research Center, Tulane University USA
| | - Ariane Vettorazzi
- Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Pharmacology and Toxicology, Campus Universitario, 31008 Pamplona, Spain
| | - Adela López de Cerain
- Universidad de Navarra, Facultad de Farmacia y Nutrición, Department of Pharmacology and Toxicology, Campus Universitario, 31008 Pamplona, Spain
| | - Eric Deharo
- UMR 152 PHARMA-DEV, Université Toulouse, IRD, UPS, 31062, Toulouse, France
| | - Xavier Fernández-Busquets
- Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, 08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal), Barcelona Center for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, 08036 Barcelona, Spain; Nanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain
| | - Giovanny Garavito
- Universidad Nacional de Colombia, Sede Bogotá, Facultad de Ciencias, Departamento de Farmacia (DFUNC), Grupo de investigación FaMeTra (Farmacología de la Medicina tradicional y popular), Carrera 30 45-03, Bogotá D.C., Colombia
| | - Ignacio Aldana
- Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Campus Universitario, 31008 Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Campus Universitario, 31008 Pamplona, Spain
| | - Silvia Galiano
- Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Campus Universitario, 31008 Pamplona, Spain; Universidad de Navarra, Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Campus Universitario, 31008 Pamplona, Spain.
| |
Collapse
|
4
|
Bonilla-Ramirez L, Jimenez-Del-Rio M, Velez-Pardo C. Low doses of paraquat and polyphenols prolong life span and locomotor activity in knock-down parkin Drosophila melanogaster exposed to oxidative stress stimuli: Implication in autosomal recessive juvenile Parkinsonism. Gene 2013; 512:355-63. [DOI: 10.1016/j.gene.2012.09.120] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2012] [Accepted: 09/29/2012] [Indexed: 11/26/2022]
|